HER2-low breast cancer reflects a group of cancers with substantial biological heterogeneity and with a HER2 immunohistochemical (IHC) score of 1+ or 2+ and a negative in situ hybridization (ISH) result [46]. This evidence concerns the gene ERBB2 and breast carcinoma.